SRES-422-119
Resolution agreed to in Senate without amendment and with a preamble by Unanimous Consent.
Sponsored by Elizabeth Warren (D-MA)
What it does
This resolution expresses the Senate's recognition of polycystic ovary syndrome (PCOS) as a serious health condition and supports designating September 2025 as "PCOS Awareness Month." It urges medical researchers and health care professionals to advance understanding of PCOS and encourages states, territories, and localities to support awareness goals. The resolution does not create law, appropriate funds, or establish any new federal program or mandate.
Who benefits
Women and girls with PCOS — estimated at roughly 10% of women in the U.S., or approximately 16–17 million people — who may benefit from increased public and clinical awareness. Patient advocacy organizations focused on PCOS and related conditions. Health care providers who may receive clearer guidance on diagnosis and treatment. Researchers who may see increased public and institutional attention directed toward PCOS funding and study. Families and partners of those affected by PCOS who may gain better understanding of the condition.
Who is hurt
No group is directly harmed by this resolution. As a purely symbolic measure with no binding legal or fiscal effect, it does not impose costs, restrictions, or obligations on any individual, organization, or government entity.
Supporters argue
Supporters argue that an estimated 70% of women with PCOS remain undiagnosed, and that raising awareness is a necessary first step toward earlier detection and treatment of a condition linked to type 2 diabetes, cardiovascular disease, endometrial cancer, and mental health disorders. They contend that the resolution's bipartisan sponsorship — spanning senators from both parties — reflects broad consensus that PCOS is a serious and underrecognized public health issue with an annual economic burden exceeding $15 billion.
Opponents argue
Opponents might argue that symbolic resolutions consume limited legislative time and floor resources without producing any enforceable change in research funding, clinical standards, or insurance coverage for PCOS patients. They could contend that the Senate's attention would be better directed toward binding legislation — such as dedicated NIH research appropriations or coverage mandates — that would produce measurable improvements in diagnosis and treatment outcomes rather than a non-binding awareness designation.